Abraxis BioScience, Inc. Reports Second Quarter 2006 Adjusted Earnings Per Share, Excluding Merger-Related Items and Stock Compensation Expense, of $0.17 versus $0.06 in the Prior Year

LOS ANGELES--(BUSINESS WIRE)--Aug. 3, 2006--Abraxis BioScience, Inc. (NASDAQ:ABBI): -- Net Sales Increase 29 Percent to $160.7 Million versus the Prior-Year Quarter -- Company Revises Guidance for ABRAXANE Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2006. The financial results for all periods presented represent the combined company formed as a result of the merger of American Pharmaceutical Partners and its parent company, American BioScience, which was completed in the second quarter.